Alpine Immune Sciences, Inc.

NasdaqGM:ALPN 주식 리포트

시가총액: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alpine Immune Sciences 경영진

경영진 기준 점검 3/4

Alpine Immune Sciences CEO는 Mitch Gold, Jun2016 에 임명되었습니다 의 임기는 7.92 년입니다. 총 연간 보상은 $2.92M, 20.5% 급여 및 79.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $860.60K 가치에 해당하는 회사 주식의 0.019% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.3 년과 6.1 년입니다.

핵심 정보

Mitch Gold

최고경영자

US$2.9m

총 보수

CEO 급여 비율20.51%
CEO 재임 기간7.9yrs
CEO 지분 보유율0.02%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간6.1yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Apr 11

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were first revealed at ASN Kidney Week In November 2023, with additional positive data just released the other day. Povetacicept is also being explored in RUBY-4 study targeting patients with autoimmune cytopenias; Data from this study will be released at a medical meeting in the 1st half of 2024. A phase 2 trial initiation, using povetacicept for the treatment of patients with systemic lupus erythematosus, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
분석 기사 • Mar 21

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) investors will be delighted, with the company turning in some strong...
분석 기사 • Mar 20

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Alpine...
Seeking Alpha • Mar 07

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the treatment of IgA nephropathy, with significant reductions in proteinuria and disease-related biomarkers. The market potential for povetacicept in the IgA nephropathy indication alone is estimated to be worth billions of dollars, making it a potentially lucrative asset for Alpine. There's plenty of competition in the IgAN space, however, including two recently approved drugs and two pipeline assets with the same MoA as povetacicept. These assets belong to Vera Therapeutics and Novartis, and it's difficult to pick a winning candidate, albeit Alpine's is the least advanced. As such, I'm not sure the company fully justifies its $2.5bn market cap - I'm on the sidelines until more data is shared. Read the full article on Seeking Alpha
분석 기사 • Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
분석 기사 • Dec 19

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
분석 기사 • Sep 23

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • May 11

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you...
분석 기사 • Dec 12

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Sep 20

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences (NASDAQ:ALPN) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an additional $15M of shares at the offering price. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
분석 기사 • Aug 09

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Apr 25

Alpine: Rest Before Rallying Again

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships. Despite not having much further catalyst this year, the company is set to release data of a Phase 1 trial studying ALPN303 by mid-year.
분석 기사 • Apr 12

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Sep 18

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Aug 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders, with the analysts...

CEO 보수 분석

Mitch Gold의 보수는 Alpine Immune Sciences의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

보상 대 시장: Mitch의 총 보수(USD2.92M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.03M)보다 낮습니다.

보상과 수익: Mitch의 보상은 회사가 적자임에도 증가했습니다.

CEO

Mitch Gold (55 yo)

7.9yrs
재임 기간
US$2,921,224
보수

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

리더십 팀

이름직위재임 기간보수지분
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
$ 860.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
$ 19.2m
Paul Rickey
Senior VP7.1yrsUS$1.28m데이터 없음
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a year데이터 없음0.044%
$ 2.0m
M. Yi
Chief Technology Officerless than a year데이터 없음데이터 없음
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Remy Durand
Chief Business Officer4.3yrs데이터 없음0.15%
$ 6.6m
Andrew Sandler
Chief Medical Officer1.8yrs데이터 없음데이터 없음
4.3yrs
평균 재임 기간
52yo
평균 나이

경험이 풍부한 관리: ALPN의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.3 년).

이사회 구성원

이름직위재임 기간보수지분
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
$ 860.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
$ 3.2m
James Topper
Independent Director7.9yrsUS$101.46k0%
$ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
$ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrs데이터 없음데이터 없음
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
$ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno data데이터 없음데이터 없음
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
$ 123.5k
John Thompson
Member of Scientific Advisory Board5.5yrs데이터 없음데이터 없음
Manish Butte
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Paul Tumeh
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
James Welsh
Member of Scientific Advisory Board5.5yrs데이터 없음데이터 없음
6.1yrs
평균 재임 기간
58yo
평균 나이

경험이 풍부한 이사회: ALPN의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.1 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2024/05/21 00:56
종가2024/05/17 00:00
수익2024/03/31
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alpine Immune Sciences, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.